# Doximity share price today (Doximity, Inc., DOCS)

> Doximity, Inc.'s P/E is near the low end of its own history, higher than only 30% of past readings, and its quarterly results are still getting worse. DOCS · Healthcare · Health Information Services · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/docs

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Getting worse, from the last 12 quarters
- Price: $32.60 (−50.6% in a year)
- P/E: 38.7× (lower than 70% of the last 4.6 years)
- Revenue (Jun 2026): $157 M (+7.3% on a year ago)
- Profit (Jun 2026): $24.3 M (−54.4% on a year ago)
- Operating margin: 21.5% (−16.3 points on a year ago)
- ROE: 21%, FY26
- ROIC: 65.7%, against a 11.3% cost of capital: +54.4 points

The main question: yearly earnings per share moved −11.7% while the share price moved −50.6%. ## What is the Doximity share price today? Doximity, Inc.'s share price was $32.60 at the close on 3 November 2026. It has been stalling near its high for 6 weeks. That is 28.0% above its average price over the last 200 trading days. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 14 weeks in a row. In the last 52 weeks it traded between $19 and $54, and at that close it sat 39% of the way up from that low. Over the last 5.4 years the share price moved −42% while the S&P 500 moved +77%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Doximity pay? Doximity, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Doximity on? Doximity is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Doximity profitable? Doximity, Inc. earned $24.3 M of net profit in the Jun 2026 quarter, −54.4% on the same quarter a year earlier. Full-year FY26 profit was $196 M. Over 4 years profit has grown 10.1% a year on average. That is 15.5% of the quarter's revenue. The same quarter a year earlier earned $53.3 M. For the full year, FY26 profit was $196 M (−12.2% on the year before). Why profit moved: revenue changed +7.3% on a year earlier and the margin moved −16.3 percentage points. Sales did the work while the margin got thinner. On average over the last four quarters, profit changed −25.3% and revenue +11.3%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Doximity make, and is it growing? Doximity, Inc. reported $157 M of revenue in the Jun 2026 quarter, +7.3% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 4 years it has grown 17.0% a year on average. The last full year, FY26, came in at $645 M. The last four reported quarters add to $656 M. FY26 revenue was $645 M, +13.1% on the year before. Recent pace: the last four quarters grew +11.3% on average, against 17.0% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +11.2%, against +15.2% a year over the last 8 quarters (rolling over); profit over the last 12 months grew −29.0%, against +2.0% a year (rolling over). ## How much of every $100 of sales does Doximity keep? Doximity, Inc.'s operating margin was 21.5% in the Jun 2026 quarter, 16.3 percentage points lower than the same quarter a year ago. Across 5 years it has been between 30.0% and 40.5%. The latest quarter is below every full year in that period. Why the margin moved: operating margin changed −16.3 percentage points on the year while gross margin changed −4.3 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Doximity's profit turning into cash? Over the last 3 years, 138% of Doximity, Inc.'s reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in $326 M of operating cash against $196 M of profit. After null of spending on assets, $326 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Doximity's cash go? Doximity, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $3.8 M on assets over the last 3 years. Averaged over those years that is 0.2% of FY26 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $3.8 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Doximity's P/E ratio, and how does it compare with its own history? Doximity, Inc.'s P/E is 38.7×, near the low end of its own history: it has been lower only 30% of the time. Its usual P/E (the middle reading) is 47.3×, over 4.6 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved −11.7% while the price moved −50.6%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 3 years the price moved +14.1% a year; about +12.8% a year came from earnings growth and about +1.3 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Doximity business getting better or worse? Doximity, Inc.'s business is getting worse. Profit and EPS growth are shrinking: profit growth is −29.0% in the latest quarter, against +51.2% at its best in 12 quarters, with ROCE falling at 20.4%. This is based on 12 quarters of 4 measures. Why it matters: falling lines mean any ratio below that looks low should be read with that direction in mind. ## How much does Doximity earn on its capital? Doximity, Inc. earned a ROE of 21% in FY26. That is up from a low of 12% in FY23. Its return on capital used (ROIC) is 54.4 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 30.4% net margin and 0.57× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 30.4% net margin × 0.57× asset turnover × 1.18× leverage (assets divided by equity) ≈ 20.4% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 65.7% − 11.3% = +54.4 percentage points. The 11.3% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. A gap this wide means each dollar put back into the business creates more than a dollar of value. The 65.7% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 88.8%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Doximity have too much debt? Doximity, Inc. has total debt of $9.7 M against shareholder equity of $916 M as of Jun 2026, so its debt is 0.01× its equity, which is very little. Year by year, that ratio went from 0.00 in FY22 to 0.01 in FY26. So the returns on this page come from the business, not from borrowed money. ## What is the Doximity shareholding pattern? 7.3% of Doximity, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 2.8 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Doximity from balance-sheet trouble? For Doximity, Inc., the Z-score is 31.30. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 31.30 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Doximity rank in its industry? 53.0 out of 100, rank 8 of 29 in Health Information Services, with 81% of the evidence available. Doximity, Inc. scores 53.0 out of 100 against the 29 companies it is compared with in Health Information Services, ranking 8. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 11.5 + 20.9 + 10.8 + 9.8 = 53. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Doximity compared with? Doximity ranks 8 of 29 Health Information Services companies on the 4-Factor Sector Score, with 53.0 out of 100. 1. [Hinge Health, Inc.](https://www.sectoralpha.in/us/stocks/hnge) HNGE · leader · Most evidence points up · 64% evidence 72.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.5/35 · Revenue 49.7% · Profit n/a · Operating margin change 436.5 points · 62% evidence Capital efficiency 19.0/25 · ROCE 27.1% · Operating margin 19% · 76% evidence Valuation 9.3/20 · P/E 59.8× · PEG n/a · 15% evidence Relative strength 17.7/20 · Lead over its industry 42% · Lead over S&P 500 75.7% · 1 year 162.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 26.5 + 19 + 9.3 + 17.7 = 72.5 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Veeva Systems Inc.](https://www.sectoralpha.in/us/stocks/veev) VEEV · breaking out · Most evidence points up · 85% evidence 69.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.9/35 · Revenue 16.5% · Profit 25.2% · Operating margin change 0.9 points · 95% evidence Capital efficiency 18.8/25 · ROCE 13.6% · Operating margin 29.6% · 76% evidence Valuation 13.0/20 · P/E 32.6× · PEG 1.3 · 65% evidence Relative strength 16.9/20 · Lead over its industry 6.4% · Lead over S&P 500 33.9% · 1 year 2.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 20.9 + 18.8 + 13 + 16.9 = 69.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [HeartFlow, Inc.](https://www.sectoralpha.in/us/stocks/htfl) HTFL · leader · Evidence leans up · 61% evidence 57.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.0/35 · Revenue 43.2% · Profit n/a · Operating margin change 3.7 points · 62% evidence Capital efficiency 4.5/25 · ROCE -24.2% · Operating margin -27.9% · 76% evidence Valuation 10.0/20 · P/E n/a · PEG n/a · 0% evidence Relative strength 19.2/20 · Lead over its industry 23.6% · Lead over S&P 500 54.5% · 1 year 67.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 24 + 4.5 + 10 + 19.2 = 57.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Waystar Holding Corp.](https://www.sectoralpha.in/us/stocks/way) WAY · breaking out · Evidence leans up · 81% evidence 55.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.7/35 · Revenue 19.4% · Profit 58.8% · Operating margin change 0.4 points · 83% evidence Capital efficiency 12.2/25 · ROCE 5.2% · Operating margin 24.4% · 76% evidence Valuation 15.6/20 · P/E 29.2× · PEG 0.64 · 65% evidence Relative strength 8.0/20 · Lead over its industry -20.2% · Lead over S&P 500 2% · 1 year -23.6% · 100% evidence · 11 of 12 weeks ahead Exact sum: 19.7 + 12.2 + 15.6 + 8 = 55.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Schrödinger, Inc.](https://www.sectoralpha.in/us/stocks/sdgr) SDGR · leader · Evidence leans up · 64% evidence 55.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.0/35 · Revenue 8.8% · Profit n/a · Operating margin change 26 points · 62% evidence Capital efficiency 4.6/25 · ROCE -32.9% · Operating margin -70.6% · 76% evidence Valuation 11.2/20 · P/E -22.3× · PEG n/a · 15% evidence Relative strength 18.5/20 · Lead over its industry 22.6% · Lead over S&P 500 53% · 1 year 52.9% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21 + 4.6 + 11.2 + 18.5 = 55.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [HealthEquity, Inc.](https://www.sectoralpha.in/us/stocks/hqy) HQY · quiet · Evidence leans up · 85% evidence 55.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.4/35 · Revenue 7.4% · Profit 62.3% · Operating margin change 0.5 points · 95% evidence Capital efficiency 16.1/25 · ROCE 11.4% · Operating margin 28.4% · 76% evidence Valuation 11.6/20 · P/E 35.6× · PEG 1.53 · 65% evidence Relative strength 6.1/20 · Lead over its industry -15.9% · Lead over S&P 500 7.3% · 1 year 8.9% · 100% evidence · 5 of 12 weeks ahead Exact sum: 21.4 + 16.1 + 11.6 + 6.1 = 55.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [BrightSpring Health Services, Inc.](https://www.sectoralpha.in/us/stocks/btsg) BTSG · turning · Too little evidence to rank firmly · 56% evidence 53.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.0/35 · Revenue n/a · Profit n/a · Operating margin change 1.6 points · 39% evidence Capital efficiency 12.6/25 · ROCE 10.1% · Operating margin 3.4% · 76% evidence Valuation 10.0/20 · P/E 39.7× · PEG n/a · 15% evidence Relative strength 11.3/20 · Lead over its industry 2.2% · Lead over S&P 500 29.7% · 1 year 110.7% · 100% evidence · 2 of 12 weeks ahead Exact sum: 20 + 12.6 + 10 + 11.3 = 53.9 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 8. Doximity, Inc. this page DOCS · breaking out · Evidence leans up · 81% evidence 53.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 11.5/35 · Revenue 11.2% · Profit -28.6% · Operating margin change -16.3 points · 83% evidence Capital efficiency 20.9/25 · ROCE 21.6% · Operating margin 21.5% · 76% evidence Valuation 10.8/20 · P/E 22.7× · PEG 1.74 · 65% evidence Relative strength 9.8/20 · Lead over its industry -17.6% · Lead over S&P 500 5.1% · 1 year -40% · 100% evidence · 12 of 12 weeks ahead Exact sum: 11.5 + 20.9 + 10.8 + 9.8 = 53 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Tempus AI, Inc.](https://www.sectoralpha.in/us/stocks/tem) TEM · breaking out · Evidence leans up · 64% evidence 51.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.1/35 · Revenue 50.2% · Profit n/a · Operating margin change -0.6 points · 62% evidence Capital efficiency 5.6/25 · ROCE -14.3% · Operating margin -19.6% · 76% evidence Valuation 11.4/20 · P/E -40.9× · PEG n/a · 15% evidence Relative strength 14.4/20 · Lead over its industry -1.4% · Lead over S&P 500 25% · 1 year 8.7% · 100% evidence · 12 of 12 weeks ahead Exact sum: 20.1 + 5.6 + 11.4 + 14.4 = 51.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Phreesia, Inc.](https://www.sectoralpha.in/us/stocks/phr) PHR · turning · Evidence leans down · 67% evidence 47.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.7/35 · Revenue 12.7% · Profit n/a · Operating margin change 7.2 points · 71% evidence Capital efficiency 9.5/25 · ROCE 4.3% · Operating margin 5.9% · 76% evidence Valuation 9.0/20 · P/E 63.5× · PEG n/a · 15% evidence Relative strength 5.7/20 · Lead over its industry -26.7% · Lead over S&P 500 -6.1% · 1 year -44.5% · 100% evidence · 7 of 12 weeks ahead Exact sum: 23.7 + 9.5 + 9 + 5.7 = 47.9 · What this means: Earnings are strong; relative strength in its sector is -26.7% and the one-year return is -44.5%. 11. [NRC Health](https://www.sectoralpha.in/us/stocks/nrc) NRC · turning · Evidence leans down · 64% evidence 47.7 out of 100 Growth Capital Valuation Relative
12. [Certara, Inc.](https://www.sectoralpha.in/us/stocks/cert) CERT · leader · Evidence leans down · 64% evidence 46.4 out of 100 Growth Capital Valuation Relative
13. [HealthStream, Inc.](https://www.sectoralpha.in/us/stocks/hstm) HSTM · leader · Evidence leans down · 81% evidence 46.2 out of 100 Growth Capital Valuation Relative
14. [Spok Holdings, Inc.](https://www.sectoralpha.in/us/stocks/spok) SPOK · turning · Evidence leans down · 81% evidence 46.1 out of 100 Growth Capital Valuation Relative
15. [American Well Corporation](https://www.sectoralpha.in/us/stocks/amwl) AMWL · losing its lead · Evidence leans down · 61% evidence 45.2 out of 100 Growth Capital Valuation Relative
16. [10x Genomics, Inc.](https://www.sectoralpha.in/us/stocks/txg) TXG · leader · Evidence leans down · 64% evidence 45.1 out of 100 Growth Capital Valuation Relative
17. [Omada Health, Inc.](https://www.sectoralpha.in/us/stocks/omda) OMDA · quiet · Evidence leans down · 64% evidence 44.9 out of 100 Growth Capital Valuation Relative
18. [Privia Health Group, Inc.](https://www.sectoralpha.in/us/stocks/prva) PRVA · basing · Evidence leans down · 81% evidence 43.0 out of 100 Growth Capital Valuation Relative
19. [Omnicell, Inc.](https://www.sectoralpha.in/us/stocks/omcl) OMCL · basing · Evidence leans down · 71% evidence 42.7 out of 100 Growth Capital Valuation Relative
20. [Carlsmed, Inc.](https://www.sectoralpha.in/us/stocks/carl) CARL · breaking out · Evidence leans down · 61% evidence 41.2 out of 100 Growth Capital Valuation Relative
21. [Teladoc Health, Inc.](https://www.sectoralpha.in/us/stocks/tdoc) TDOC · turning · Evidence leans down · 61% evidence 41.2 out of 100 Growth Capital Valuation Relative
22. [Claritev Corporation](https://www.sectoralpha.in/us/stocks/ctev) CTEV · quiet · Evidence leans down · 64% evidence 37.4 out of 100 Growth Capital Valuation Relative
23. [SOPHiA GENETICS SA](https://www.sectoralpha.in/us/stocks/soph) SOPH · losing its lead · Evidence leans down · 61% evidence 37.1 out of 100 Growth Capital Valuation Relative
24. [Evolent Health, Inc.](https://www.sectoralpha.in/us/stocks/evh) EVH · turning · Evidence leans down · 64% evidence 36.9 out of 100 Growth Capital Valuation Relative
25. [GoodRx Holdings, Inc.](https://www.sectoralpha.in/us/stocks/gdrx) GDRX · quiet · Most evidence points down · 81% evidence 33.9 out of 100 Growth Capital Valuation Relative
26. [Simulations Plus, Inc.](https://www.sectoralpha.in/us/stocks/slp) SLP · Too little evidence to rank firmly · 44% evidence 56.3 out of 100 Growth Capital Valuation Relative
27. [Talkspace, Inc.](https://www.sectoralpha.in/us/stocks/talk) TALK · Too little evidence to rank firmly · 44% evidence 48.4 out of 100 Growth Capital Valuation Relative
28. [Weave Communications, Inc.](https://www.sectoralpha.in/us/stocks/weav) WEAV · Too little evidence to rank firmly · 41% evidence 47.7 out of 100 Growth Capital Valuation Relative
29. [TruBridge, Inc.](https://www.sectoralpha.in/us/stocks/tbrg) TBRG · Too little evidence to rank firmly · 31% evidence 42.2 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Health Information Services](https://www.sectoralpha.in/us/sectors/health-information-services), all 29 compared on one page. ## Which companies are close to Doximity in size? Doximity is the 7th largest of 30 Health Information Services companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: Hinge Health, Inc., 10x Genomics, Inc. and HealthEquity, Inc. Just below it: Waystar Holding Corp., HeartFlow, Inc. and Privia Health Group, Inc. ### Health Information Services companies close in size

1. [Hinge Health, Inc.](https://www.sectoralpha.in/us/stocks/hnge) $9.4 billion
2. [10x Genomics, Inc.](https://www.sectoralpha.in/us/stocks/txg) $8.5 billion
3. [HealthEquity, Inc.](https://www.sectoralpha.in/us/stocks/hqy) $8.4 billion
4. Doximity, Inc. $5.8 billion
5. [Waystar Holding Corp.](https://www.sectoralpha.in/us/stocks/way) $5.3 billion
6. [HeartFlow, Inc.](https://www.sectoralpha.in/us/stocks/htfl) $4.7 billion
7. [Privia Health Group, Inc.](https://www.sectoralpha.in/us/stocks/prva) $2.7 billion

[All 30 Health Information Services companies, largest first](https://www.sectoralpha.in/us/sectors/health-information-services#all-companies)

### Companies close in size in other industries

1. [Lear Corporation](https://www.sectoralpha.in/us/stocks/lea) $5.9 billion · Auto Parts
2. [Hims & Hers Health, Inc.](https://www.sectoralpha.in/us/stocks/hims) $5.9 billion · Drug Manufacturers - Specialty & Generic
3. Doximity, Inc. $5.9 billion
4. [NIQ Global Intelligence plc](https://www.sectoralpha.in/us/stocks/niq) $5.9 billion · Information Technology Services
5. [Hancock Whitney Corporation](https://www.sectoralpha.in/us/stocks/hwc) $5.8 billion · Banks - Regional

## What else do people ask about Doximity? ### What were Doximity's latest quarterly results? Doximity, Inc. reported revenue of $157 M and net profit of $24.3 M for the Jun 2026 quarter. Revenue rose 7.3% and profit fell 54.4% compared with a year earlier. Earnings per share were $0.13. The operating margin was 21.5%, 16.3 percentage points lower than a year earlier (as of 3 November 2026). ### What is Doximity's market cap? Doximity, Inc.'s market capitalisation is $5.8 B at a stock price of $32.60. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Doximity performing? Doximity, Inc.'s share price has been stalling near its high for 6 weeks. In its latest quarter, revenue rose 7.3% and profit fell 54.4% compared with a year earlier. Over the past 13 weeks it has done better than the S&P 500, for 14 weeks running (as of 3 November 2026). ### Will Doximity's stock price go up? This page does not forecast Doximity, Inc.'s stock price. What it shows instead: the stock price is $32.60, and it has been stalling near its high for 6 weeks. Its P/E of 38.7× is higher than 30% of its own last 5 years (as of 3 November 2026). ### What is Doximity's capex? Doximity, Inc. spent $3.8 M on capital expenditure (new plants, machines and other long-term assets) over the last 3 years, worked out from the change in fixed assets plus depreciation. In FY24 alone that was $147 K (as of 3 November 2026). ### Where is Doximity in its business cycle? Doximity, Inc.'s FY26 operating margin was 34.4%, against a 5-year range of 30.0% to 40.5%: the middle of its own range, neither a peak nor a low. The latest quarter was 21.5%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Doximity story? The main question: yearly earnings per share moved −11.7% while the share price moved −50.6%. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Doximity a stock worth studying right now? What the numbers show: Doximity, Inc.'s P/E is near the low end of its own history, higher than only 30% of past readings, and its quarterly results are still getting worse. The main open question: whether the price catches up with earnings that have already grown. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.